An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.

The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brad Brown, Marc Allard, Michael C Bazaco, Joseph Blankenship, Travis Minor
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4cb8d53c04fe42a48f008279233dcd42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4cb8d53c04fe42a48f008279233dcd42
record_format	dspace
spelling	oai:doaj.org-article:4cb8d53c04fe42a48f008279233dcd422021-12-02T20:17:15ZAn economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.1932-620310.1371/journal.pone.0258262https://doaj.org/article/4cb8d53c04fe42a48f008279233dcd422021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0258262https://doaj.org/toc/1932-6203The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures.Brad BrownMarc AllardMichael C BazacoJoseph BlankenshipTravis MinorPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0258262 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Brad Brown Marc Allard Michael C Bazaco Joseph Blankenship Travis Minor An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
description	The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures.
format	article
author	Brad Brown Marc Allard Michael C Bazaco Joseph Blankenship Travis Minor
author_facet	Brad Brown Marc Allard Michael C Bazaco Joseph Blankenship Travis Minor
author_sort	Brad Brown
title	An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_short	An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_full	An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_fullStr	An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_full_unstemmed	An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_sort	economic evaluation of the whole genome sequencing source tracking program in the u.s.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/4cb8d53c04fe42a48f008279233dcd42
work_keys_str_mv	AT bradbrown aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT marcallard aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT michaelcbazaco aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT josephblankenship aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT travisminor aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT bradbrown economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT marcallard economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT michaelcbazaco economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT josephblankenship economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT travisminor economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
_version_	1718374404164943872

An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.

Ejemplares similares